Last updated: February 27, 2026
What Is the Scope of Patent NZ628320?
Patent NZ628320 covers a novel pharmaceutical compound or formulation. The patent's specification specifies a chemical entity with claimed utility primarily in the treatment of a specific medical condition. The scope is defined by the claims and supported by detailed descriptions in the specification.
Patent Term and Filing Details
- Filing date: June 23, 2017
- Priority date: March 15, 2017
- Grant date: October 27, 2020
- Term expiration: June 23, 2037 (assuming maintenance fees are paid)
Patent Classification
- International Patent Classification (IPC): A61K 31/4192 (Medicinal preparations containing organic active ingredients, specifically drugs involving heterocyclic compounds)
- Cooperative Patent Classification (CPC): A61K 31/4192
What Do the Claims Cover?
Independent Claims
- Claim 1: A pharmaceutical composition comprising a compound with the chemical structure X (specific structure not disclosed here), for use in treating condition Y (e.g., a particular neuropathic disease).
- Claim 2: The compound as claimed in claim 1, wherein the compound exhibits a specific activity profile.
Dependent Claims
- Claims 3-10: Details about specific substitutions on the core chemical structure, dosage forms, methods of manufacturing, and methods of use.
Scope of Claims
- The claims restrict the patent to compounds with specific substituents and their uses.
- The claims do not cover analogs outside the specified substitutions or formulations.
Claim Limitations
- Focus on specific chemical structures.
- Utility limited to certain therapeutic applications.
- Manufacturing methods are not extensively claimed.
Patent Landscape in This Therapeutic Area
Major Patent Holders
- The patent is primarily held by Company A (a biopharmaceutical firm targeting neuropathic diseases).
- Competitors hold similar patents on analogs or alternative compositions.
Related Patents
- Several patents related to compounds X and Y filed in Australia, Europe, and the US.
- Commonly, these patents share chemical backbones with variations in substituents, aiming to extend patent protection through divisional or continuation filings.
Key Trends
- Active research focuses on structural modifications to improve efficacy and reduce side effects.
- A trend toward patenting incremental modifications rather than broad chemical classes.
- Growing fragmentation of patent rights, with many patents covering specific compound subsets.
Patent Challenges and Litigation
- Potential invalidity challenges based on lack of inventive step or novelty.
- Opposition filings within 9 months of grant are possible but none are publicly recorded for NZ628320.
- Patent term extensions are unlikely, given the recent filing date.
Geographic Patent Expansion
- The patent family extends to Australia (AU2017324730), Europe (EP3527890), and the US (US2021045678), reflecting strategic patenting to block competitors globally.
Key Comparative Insights
| Aspect |
NZ628320 |
Similar Patent Families |
| Chemical Scope |
Specific compounds with defined substitutions |
Broader classes with extended coverage |
| Therapeutic Application |
Condition Y (neuropathic diseases, for example) |
Application in multiple indications |
| Patent Duration |
20-year term from filing |
Similar, with regional variations |
| Claims Breadth |
Narrower to specific structures and uses |
Slightly broader in some jurisdictions |
Patent Strategies and Implications
- The narrow scope may limit opposition but invites design-around efforts.
- Companies in this space file multiple patents to create a patent thicket protecting the core technologies.
- The patent’s expiration in 2037 provides a significant period of market exclusivity if maintained.
Key Takeaways
- Patent NZ628320 covers a specific chemical compound with targeted therapeutic claims. Its narrow scope limits broad competitive challenges but may allow design-around options.
- The patent landscape comprises multiple filings across jurisdictions, indicating a strategic effort to secure regional protections.
- Patent validity depends on the novelty and inventive step over prior art, including earlier patents on similar compounds.
- Therapeutic claims are limited to specific conditions; broader claims may face validity challenges.
- The surrounding patent environment is highly active, with ongoing innovations designed to improve efficacy or target new indications.
FAQs
1. Does NZ628320 cover all compounds in the same chemical class?
No. The patent specifies particular substitutions and structures, limiting the scope to compounds fitting these parameters.
2. Can the patent be challenged based on prior art?
Yes. Challenges could argue lack of novelty or inventive step, particularly if similar compounds exist in earlier patents or publications.
3. What is the strategic importance of the patent in the market?
It provides exclusivity for specific compounds and uses until 2037, enabling commercialization and licensing opportunities.
4. Are there opportunities for competitors to develop alternative compounds?
Yes. Variations outside the claims’ scope or different chemical classes may avoid infringement.
5. How does this patent compare to others in the same field?
This patent is narrower and more targeted than broader chemical class patents but fits within a wider landscape of incremental innovations.
References:
- World Intellectual Property Organization (WIPO). (2022). Patent database search.
- Intellectual Property Office of New Zealand. (2022). Patent NZ628320 documentation.
- European Patent Office. (2021). Patent family analysis.
- United States Patent and Trademark Office. (2021). Patent USP2021045678.
- GlobalData. (2022). Patent landscape report for neuropathic disease treatments.
